Novartis

News

Novartis will appeal Entresto patent setback

Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t

News

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f

News

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte

News

Cosentyx nod ends 10-year drought in new biologics for HS

Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i

News

Novartis buys Pharming priority review voucher for a song

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate.

News

EU approval for Novartis’ sickle cell drug set to be pulled

Novartis has said it is “disappointed” that the EMA’s Human Medicines Committee has recommended revoking the conditional EU approval for sickle cell disease (SCD) therapy

Novartis will appeal Entresto patent setback

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Cosentyx nod ends 10-year drought in new biologics for HS

Novartis buys Pharming priority review voucher for a song

EU approval for Novartis’ sickle cell drug set to be pulled

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Novartis

Editor's Picks